Systematic Financial Management LP trimmed its holdings in Celgene Corporation (NASDAQ:CELG) by 5.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,609 shares of the biopharmaceutical company’s stock after selling 1,310 shares during the period. Systematic Financial Management LP’s holdings in Celgene Corporation were worth $2,806,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of CELG. Montecito Bank & Trust grew its position in Celgene Corporation by 12.8% in the first quarter. Montecito Bank & Trust now owns 2,710 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 307 shares in the last quarter. Allegis Investment Advisors LLC boosted its holdings in shares of Celgene Corporation by 71.2% during the 1st quarter. Allegis Investment Advisors LLC now owns 21,268 shares of the biopharmaceutical company’s stock worth $2,646,000 after buying an additional 8,844 shares during the period. Karp Capital Management Corp bought a new stake in shares of Celgene Corporation during the 1st quarter worth $49,750,000. Tdam USA Inc. boosted its holdings in shares of Celgene Corporation by 2.1% during the 1st quarter. Tdam USA Inc. now owns 27,084 shares of the biopharmaceutical company’s stock worth $3,370,000 after buying an additional 570 shares during the period. Finally, YorkBridge Wealth Partners LLC boosted its holdings in shares of Celgene Corporation by 27.6% during the 1st quarter. YorkBridge Wealth Partners LLC now owns 11,915 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 2,574 shares during the period. 79.16% of the stock is owned by institutional investors.
In other news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the completion of the sale, the director now owns 9,250 shares in the company, valued at $1,286,027.50. The disclosure for this sale can be found here. Insiders have sold a total of 20,227 shares of company stock worth $2,843,956 over the last 90 days. Corporate insiders own 0.95% of the company’s stock.
Several analysts recently issued reports on the stock. Morgan Stanley downgraded shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Thursday, October 5th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $173.00 price objective on shares of Celgene Corporation in a report on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a report on Thursday, September 21st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a report on Tuesday, September 26th. Finally, Bank of America Corporation reiterated a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $139.64.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/13/systematic-financial-management-lp-sells-1310-shares-of-celgene-corporation-celg.html.
Shares of Celgene Corporation (NASDAQ CELG) opened at $102.34 on Monday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The company has a market cap of $80,574.02, a P/E ratio of 15.99, a price-to-earnings-growth ratio of 0.79 and a beta of 1.79. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17.
Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the company posted $1.58 EPS. equities analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.